Central New Hampshire Kidney Center is a medicare approved dialysis facility center in Laconia, New Hampshire and it has 21 dialysis stations. It is located in Belknap county at 87 Spring Street, Laconia, NH, 03246. You can reach out to the office of Central New Hampshire Kidney Center at (603) 528-3738. This dialysis clinic is run as an Independent entity i.e it is not owned by any chain organization. Central New Hampshire Kidney Center has the following ownership type - Profit. It was first certified by medicare in February, 1990. The medicare id for this facility is 302503 and it accepts patients under medicare ESRD program.
| Name | Central New Hampshire Kidney Center |
|---|---|
| Location | 87 Spring Street, Laconia, New Hampshire |
| No. of Dialysis Stations | 21 |
| Medicare ID | 302503 |
| Managed By | Independent |
| Ownership Type | Profit |
| Late Shifts | No |
| 87 Spring Street, Laconia, New Hampshire, 03246 | |
| (603) 528-3738 | |
News Archive
Flamel Technologies today announced that Pfizer (NYSE:PFE) has exercised its option to license Flamel's Medusa® technology for the development of a controlled release formulation of an already-marketed therapeutic protein.
In a report released Wednesday, New York-based Human Rights Watch "accused the United States government, the World Bank and other international donors of indirectly funding forced labor in Vietnam's drug rehabilitation centers," Inter Press Service reports.
STB Lifesaving Technologies® today announced that is has completed a successful pre-Investigational New Drug (pre-IND) submission to the U.S. Food and Drug Administration (FDA) for its lead product, the Fibrin Adhesive STat®, or (FAST®) dressing.
Researchers at UC San Francisco and UC Berkeley have teamed up to create an innovative, integrated center for research on neurodegenerative diseases. Supported by a $3 million grant from the Glenn Foundation for Medical Research, the new center aims to pave the way to developing novel treatments for diseases such as Alzheimer's disease and Parkinson's disease by investigating the many ways that proteins can malfunction within cells.
› Verified 2 days ago
| NPI Number | 1679698765 |
| Doing Business As | Central New Hampshire Kidney Center,llc |
| Address | 87 Spring Street Laconia, New Hampshire, 03246 |
| Phone Number | (603) 528-3738 |
News Archive
Flamel Technologies today announced that Pfizer (NYSE:PFE) has exercised its option to license Flamel's Medusa® technology for the development of a controlled release formulation of an already-marketed therapeutic protein.
In a report released Wednesday, New York-based Human Rights Watch "accused the United States government, the World Bank and other international donors of indirectly funding forced labor in Vietnam's drug rehabilitation centers," Inter Press Service reports.
STB Lifesaving Technologies® today announced that is has completed a successful pre-Investigational New Drug (pre-IND) submission to the U.S. Food and Drug Administration (FDA) for its lead product, the Fibrin Adhesive STat®, or (FAST®) dressing.
Researchers at UC San Francisco and UC Berkeley have teamed up to create an innovative, integrated center for research on neurodegenerative diseases. Supported by a $3 million grant from the Glenn Foundation for Medical Research, the new center aims to pave the way to developing novel treatments for diseases such as Alzheimer's disease and Parkinson's disease by investigating the many ways that proteins can malfunction within cells.
› Verified 2 days ago
| Dialysis patients with Hemoglobin data | 28 |
| Medicare patients who had average hemoglobin (hgb) less than 10 g/dL | 21 |
News Archive
Flamel Technologies today announced that Pfizer (NYSE:PFE) has exercised its option to license Flamel's Medusa® technology for the development of a controlled release formulation of an already-marketed therapeutic protein.
In a report released Wednesday, New York-based Human Rights Watch "accused the United States government, the World Bank and other international donors of indirectly funding forced labor in Vietnam's drug rehabilitation centers," Inter Press Service reports.
STB Lifesaving Technologies® today announced that is has completed a successful pre-Investigational New Drug (pre-IND) submission to the U.S. Food and Drug Administration (FDA) for its lead product, the Fibrin Adhesive STat®, or (FAST®) dressing.
Researchers at UC San Francisco and UC Berkeley have teamed up to create an innovative, integrated center for research on neurodegenerative diseases. Supported by a $3 million grant from the Glenn Foundation for Medical Research, the new center aims to pave the way to developing novel treatments for diseases such as Alzheimer's disease and Parkinson's disease by investigating the many ways that proteins can malfunction within cells.
› Verified 2 days ago
Adult patinets who undergo hemodialysis, their Kt/V should be atleast 1.2 and for peritoneal dialysis the Kt/V should be atleast 1.7, that means they are receiving right amount of dialysis. Pediatric patients who undergo hemodialysis, their Kt/V should be atleast 1.2 and for peritoneal dialysis the Kt/V should be 1.8.
Higher percentages should be better.
| Adult patients getting regular hemodialysis at the center | 53 |
| Adult patient months included in Kt/V greater than or equal to 1.2 | 427 |
| Percentage of adult patients getting regular hemodialysis at the center | 97 |
| Percentage of pediatric patients getting regular hemodialysis at the center |
News Archive
Flamel Technologies today announced that Pfizer (NYSE:PFE) has exercised its option to license Flamel's Medusa® technology for the development of a controlled release formulation of an already-marketed therapeutic protein.
In a report released Wednesday, New York-based Human Rights Watch "accused the United States government, the World Bank and other international donors of indirectly funding forced labor in Vietnam's drug rehabilitation centers," Inter Press Service reports.
STB Lifesaving Technologies® today announced that is has completed a successful pre-Investigational New Drug (pre-IND) submission to the U.S. Food and Drug Administration (FDA) for its lead product, the Fibrin Adhesive STat®, or (FAST®) dressing.
Researchers at UC San Francisco and UC Berkeley have teamed up to create an innovative, integrated center for research on neurodegenerative diseases. Supported by a $3 million grant from the Glenn Foundation for Medical Research, the new center aims to pave the way to developing novel treatments for diseases such as Alzheimer's disease and Parkinson's disease by investigating the many ways that proteins can malfunction within cells.
› Verified 2 days ago
An important goal of dialysis is to maintain normal levels of various minerals in the body, such as calcium. This shows the percentage of patients treated at Central New Hampshire Kidney Center with elevated calcium levels.
| Patients with hypercalcemia | 54 |
| Hypercalcemia patient months | 439 |
| Patients with Serumphosphor | 59 |
| Patients with Serumphosphor less than 3.5 mg/dL | 12 |
| Patients with Serumphosphor from 3.5 to 4.5 mg/dL | 23 |
| Patients with Serumphosphor from 4.6 to 5.5 mg/dL | 18 |
| Patients with Serumphosphor from 5.6 to 7 mg/dL | 25 |
| Patients with Serumphosphor greater than 7 mg/dL | 22 |
News Archive
Flamel Technologies today announced that Pfizer (NYSE:PFE) has exercised its option to license Flamel's Medusa® technology for the development of a controlled release formulation of an already-marketed therapeutic protein.
In a report released Wednesday, New York-based Human Rights Watch "accused the United States government, the World Bank and other international donors of indirectly funding forced labor in Vietnam's drug rehabilitation centers," Inter Press Service reports.
STB Lifesaving Technologies® today announced that is has completed a successful pre-Investigational New Drug (pre-IND) submission to the U.S. Food and Drug Administration (FDA) for its lead product, the Fibrin Adhesive STat®, or (FAST®) dressing.
Researchers at UC San Francisco and UC Berkeley have teamed up to create an innovative, integrated center for research on neurodegenerative diseases. Supported by a $3 million grant from the Glenn Foundation for Medical Research, the new center aims to pave the way to developing novel treatments for diseases such as Alzheimer's disease and Parkinson's disease by investigating the many ways that proteins can malfunction within cells.
› Verified 2 days ago
The arteriovenous (AV) fistulae is considered long term vascular access for hemodialysis because it allows good blood flow, lasts a long time, and is less likely to get infected or cause blood clots than other types of access. Patients who don't have time to get a permanent vascular access before they start hemodialysis treatments may need to use a venous catheter as a temporary access.
| Patients included in arterial venous fistula and catheter summaries | 61 |
| Patient months included in arterial venous fistula and catheter summaries | 410 |
| Percentage of patients getting regular hemodialysis at the center that used an arteriovenous (AV) fistulae for their treatment | 67 |
| Percentage of patients receiving treatment through Vascular Catheter for 90 days/longer | 16 |
News Archive
Flamel Technologies today announced that Pfizer (NYSE:PFE) has exercised its option to license Flamel's Medusa® technology for the development of a controlled release formulation of an already-marketed therapeutic protein.
In a report released Wednesday, New York-based Human Rights Watch "accused the United States government, the World Bank and other international donors of indirectly funding forced labor in Vietnam's drug rehabilitation centers," Inter Press Service reports.
STB Lifesaving Technologies® today announced that is has completed a successful pre-Investigational New Drug (pre-IND) submission to the U.S. Food and Drug Administration (FDA) for its lead product, the Fibrin Adhesive STat®, or (FAST®) dressing.
Researchers at UC San Francisco and UC Berkeley have teamed up to create an innovative, integrated center for research on neurodegenerative diseases. Supported by a $3 million grant from the Glenn Foundation for Medical Research, the new center aims to pave the way to developing novel treatments for diseases such as Alzheimer's disease and Parkinson's disease by investigating the many ways that proteins can malfunction within cells.
› Verified 2 days ago
The rate of hospitalization show you whether patients who were being treated regularly at a certain dialysis center were admitted to the hospital more often (worse than expected), less often (better than expected), or about the same (as expected), compared to similar patients treated at other centers.
| Standard Hospitalization Summary Ratio(SHR) Year | January, 2016 - December, 2016 |
| Patients in facility's Hospitalization Summary | 44 |
| Hospitalization Rate in facility | 133.8 (As Expected) |
| Hospitalization Rate: Upper Confidence Limit | 260 |
| Hospitalization Rate: Lower Confidence Limit | 72.2 |
News Archive
Flamel Technologies today announced that Pfizer (NYSE:PFE) has exercised its option to license Flamel's Medusa® technology for the development of a controlled release formulation of an already-marketed therapeutic protein.
In a report released Wednesday, New York-based Human Rights Watch "accused the United States government, the World Bank and other international donors of indirectly funding forced labor in Vietnam's drug rehabilitation centers," Inter Press Service reports.
STB Lifesaving Technologies® today announced that is has completed a successful pre-Investigational New Drug (pre-IND) submission to the U.S. Food and Drug Administration (FDA) for its lead product, the Fibrin Adhesive STat®, or (FAST®) dressing.
Researchers at UC San Francisco and UC Berkeley have teamed up to create an innovative, integrated center for research on neurodegenerative diseases. Supported by a $3 million grant from the Glenn Foundation for Medical Research, the new center aims to pave the way to developing novel treatments for diseases such as Alzheimer's disease and Parkinson's disease by investigating the many ways that proteins can malfunction within cells.
› Verified 2 days ago
The rate of readmission show you whether patients who were being treated regularly at Central New Hampshire Kidney Center were readmitted more often (worse than expected), less often (better than expected), or about the same (as expected), compared to similar patients treated at other dialysis centers.
| Standard Readmission Summary Ratio(SRR) Year | January, 2016 - December, 2016 |
| Readmission Rate in facility | 14.8 (As Expected) |
| Readmission Rate: Upper Confidence Limit | 31.1 |
| Readmission Rate: Lower Confidence Limit | 5.2 |
News Archive
Flamel Technologies today announced that Pfizer (NYSE:PFE) has exercised its option to license Flamel's Medusa® technology for the development of a controlled release formulation of an already-marketed therapeutic protein.
In a report released Wednesday, New York-based Human Rights Watch "accused the United States government, the World Bank and other international donors of indirectly funding forced labor in Vietnam's drug rehabilitation centers," Inter Press Service reports.
STB Lifesaving Technologies® today announced that is has completed a successful pre-Investigational New Drug (pre-IND) submission to the U.S. Food and Drug Administration (FDA) for its lead product, the Fibrin Adhesive STat®, or (FAST®) dressing.
Researchers at UC San Francisco and UC Berkeley have teamed up to create an innovative, integrated center for research on neurodegenerative diseases. Supported by a $3 million grant from the Glenn Foundation for Medical Research, the new center aims to pave the way to developing novel treatments for diseases such as Alzheimer's disease and Parkinson's disease by investigating the many ways that proteins can malfunction within cells.
› Verified 2 days ago
Hemodialysis treatment requires direct access to the bloodstream, which can be an opportunity for germs to enter the body and cause infection. This information shows how often patients at Central New Hampshire Kidney Center get infections in their blood each year compared to the number of infections expected for the center based on the national average.
| Standard Infection Summary Ratio(SIR) Year | January, 2016 - December, 2016 |
| Infection Rate in facility | .83 (As Expected) |
| SIR: Upper Confidence Limit | 2.25 |
| SIR: Lower Confidence Limit | .21 |
News Archive
Flamel Technologies today announced that Pfizer (NYSE:PFE) has exercised its option to license Flamel's Medusa® technology for the development of a controlled release formulation of an already-marketed therapeutic protein.
In a report released Wednesday, New York-based Human Rights Watch "accused the United States government, the World Bank and other international donors of indirectly funding forced labor in Vietnam's drug rehabilitation centers," Inter Press Service reports.
STB Lifesaving Technologies® today announced that is has completed a successful pre-Investigational New Drug (pre-IND) submission to the U.S. Food and Drug Administration (FDA) for its lead product, the Fibrin Adhesive STat®, or (FAST®) dressing.
Researchers at UC San Francisco and UC Berkeley have teamed up to create an innovative, integrated center for research on neurodegenerative diseases. Supported by a $3 million grant from the Glenn Foundation for Medical Research, the new center aims to pave the way to developing novel treatments for diseases such as Alzheimer's disease and Parkinson's disease by investigating the many ways that proteins can malfunction within cells.
› Verified 2 days ago
Patients with anemia require blood transfusions if their anemia is not managed well by their dialysis center. This information shows whether Central New Hampshire Kidney Center's rate of transfusions is better than expected, as expected, or worse than expected, compared to other centers that treat similar patients.
| Standard Transfusion Summary Ratio (STrR) Year | January, 2016 - December, 2016 |
| Patients in facility's Transfusion Summary | 40 |
| Transfusion Rate in facility | 36.8 (As Expected) |
| Transfusion Rate: Upper Confidence Limit | 112.4 |
| Transfusion Rate: Lower Confidence Limit | 13.8 |
News Archive
Flamel Technologies today announced that Pfizer (NYSE:PFE) has exercised its option to license Flamel's Medusa® technology for the development of a controlled release formulation of an already-marketed therapeutic protein.
In a report released Wednesday, New York-based Human Rights Watch "accused the United States government, the World Bank and other international donors of indirectly funding forced labor in Vietnam's drug rehabilitation centers," Inter Press Service reports.
STB Lifesaving Technologies® today announced that is has completed a successful pre-Investigational New Drug (pre-IND) submission to the U.S. Food and Drug Administration (FDA) for its lead product, the Fibrin Adhesive STat®, or (FAST®) dressing.
Researchers at UC San Francisco and UC Berkeley have teamed up to create an innovative, integrated center for research on neurodegenerative diseases. Supported by a $3 million grant from the Glenn Foundation for Medical Research, the new center aims to pave the way to developing novel treatments for diseases such as Alzheimer's disease and Parkinson's disease by investigating the many ways that proteins can malfunction within cells.
› Verified 2 days ago
The rate of mortality show you whether patients who were being treated regularly at Central New Hampshire Kidney Center lived longer than expected (better than expected), don’t live as long as expected (worse than expected), or lived as long as expected (as expected), compared to similar patients treated at other facilities.
| Standard Survival Summary Ratio(SIR) Year | January, 2013 - December, 2016 |
| Patients in facility's Survival Summary | 225 |
| Mortality Rate in facility | 17.8 (As Expected) |
| Mortality Rate: Upper Confidence Limit | 24.5 |
| Mortality Rate: Lower Confidence Limit | 12.6 |
News Archive
Flamel Technologies today announced that Pfizer (NYSE:PFE) has exercised its option to license Flamel's Medusa® technology for the development of a controlled release formulation of an already-marketed therapeutic protein.
In a report released Wednesday, New York-based Human Rights Watch "accused the United States government, the World Bank and other international donors of indirectly funding forced labor in Vietnam's drug rehabilitation centers," Inter Press Service reports.
STB Lifesaving Technologies® today announced that is has completed a successful pre-Investigational New Drug (pre-IND) submission to the U.S. Food and Drug Administration (FDA) for its lead product, the Fibrin Adhesive STat®, or (FAST®) dressing.
Researchers at UC San Francisco and UC Berkeley have teamed up to create an innovative, integrated center for research on neurodegenerative diseases. Supported by a $3 million grant from the Glenn Foundation for Medical Research, the new center aims to pave the way to developing novel treatments for diseases such as Alzheimer's disease and Parkinson's disease by investigating the many ways that proteins can malfunction within cells.
› Verified 2 days ago
Central New Hampshire Kidney Center Location: 87 Spring Street, Laconia, New Hampshire, 03246 Phone: (603) 528-3738 |
News Archive
Flamel Technologies today announced that Pfizer (NYSE:PFE) has exercised its option to license Flamel's Medusa® technology for the development of a controlled release formulation of an already-marketed therapeutic protein.
In a report released Wednesday, New York-based Human Rights Watch "accused the United States government, the World Bank and other international donors of indirectly funding forced labor in Vietnam's drug rehabilitation centers," Inter Press Service reports.
STB Lifesaving Technologies® today announced that is has completed a successful pre-Investigational New Drug (pre-IND) submission to the U.S. Food and Drug Administration (FDA) for its lead product, the Fibrin Adhesive STat®, or (FAST®) dressing.
Researchers at UC San Francisco and UC Berkeley have teamed up to create an innovative, integrated center for research on neurodegenerative diseases. Supported by a $3 million grant from the Glenn Foundation for Medical Research, the new center aims to pave the way to developing novel treatments for diseases such as Alzheimer's disease and Parkinson's disease by investigating the many ways that proteins can malfunction within cells.
› Verified 2 days ago